GAD65 antibodies, chronic psychosis, and type 2 diabetes mellitus

Autor: Yarlagadda A, Jerome Henry Taylor, Cs, Hampe, Alfson E, Ah, Clayton

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b814d1f352f3577724ec9b5c16433a19
http://europepmc.org/abstract/med/21922068

Factorial Trial to Optimize an Internet-Delivered Intervention for Sexual Health After Breast Cancer: Protocol for the WF-2202 Sexual Health and Intimacy Enhancement (SHINE) Trial.

Autor: Shaffer KM; University of Virginia School of Medicine, Charlottesville, VA, United States., Reese JB; Fox Chase Cancer Center, Philadelphia, PA, United States., Dressler EV; Wake Forest University School of Medicine, Winston-Salem, NC, United States., Glazer JV; University of Virginia School of Medicine, Charlottesville, VA, United States., Cohn W; University of Virginia School of Medicine, Charlottesville, VA, United States., Showalter SL; University of Virginia School of Medicine, Charlottesville, VA, United States., Clayton AH; University of Virginia School of Medicine, Charlottesville, VA, United States., Danhauer SC; Wake Forest University School of Medicine, Winston-Salem, NC, United States., Loch M; Louisiana State University Health Sciences Center, New Orleans, LA, United States., Kadi M; University of Virginia School of Medicine, Charlottesville, VA, United States., Smith C; University of Virginia School of Medicine, Charlottesville, VA, United States., Weaver KE; Wake Forest University School of Medicine, Winston-Salem, NC, United States., Lesser GJ; Wake Forest University School of Medicine, Winston-Salem, NC, United States., Ritterband LM; University of Virginia School of Medicine, Charlottesville, VA, United States.

Publikováno v: JMIR research protocols [JMIR Res Protoc] 2024 Aug 19; Vol. 13, pp. e57781. Date of Electronic Publication: 2024 Aug 19.

Outpatient Pharmacogenomic Screenings to Prevent Addiction, Overdose, and Suicide.

Autor: Yarlagadda A; Dr. Yarlagadda is Installation Director of Psychological Health at McDonald Army Health Center in Fort Eustis, Virginia., Swift K; Drs. Swift, Chakraborty, and Hammamieh are with Medical Readiness Systems Biology, Walter Reed Army Institute of Research in Silver Spring, Maryland., Chakraborty N; Drs. Swift, Chakraborty, and Hammamieh are with Medical Readiness Systems Biology, Walter Reed Army Institute of Research in Silver Spring, Maryland., Hammamieh R; Drs. Swift, Chakraborty, and Hammamieh are with Medical Readiness Systems Biology, Walter Reed Army Institute of Research in Silver Spring, Maryland., Abubakar A; Drs. Abubakar and Wilbur are with Avant Institute in Charlotte, North Carolina., Wilbur M; Drs. Abubakar and Wilbur are with Avant Institute in Charlotte, North Carolina., Clayton AH; Dr. Clayton is with Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine in Charlottesville, Virginia.

Publikováno v: Innovations in clinical neuroscience [Innov Clin Neurosci] 2023 Dec 01; Vol. 20 (10-12), pp. 12-17. Date of Electronic Publication: 2023 Dec 01 (Print Publication: 2023).

Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.

Autor: Clayton AH; Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville (Clayton); Sage Therapeutics, Cambridge, Mass. (Lasser, Jung, Jonas, Kanes, Doherty); Department of Psychiatry, University of Michigan, Ann Arbor (Parikh); Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, New York (Iosifescu); Biogen, Cambridge, Mass. (Kotecha, Forrestal)., Lasser R; Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville (Clayton); Sage Therapeutics, Cambridge, Mass. (Lasser, Jung, Jonas, Kanes, Doherty); Department of Psychiatry, University of Michigan, Ann Arbor (Parikh); Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, New York (Iosifescu); Biogen, Cambridge, Mass. (Kotecha, Forrestal)., Parikh SV; Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville (Clayton); Sage Therapeutics, Cambridge, Mass. (Lasser, Jung, Jonas, Kanes, Doherty); Department of Psychiatry, University of Michigan, Ann Arbor (Parikh); Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, New York (Iosifescu); Biogen, Cambridge, Mass. (Kotecha, Forrestal)., Iosifescu DV; Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville (Clayton); Sage Therapeutics, Cambridge, Mass. (Lasser, Jung, Jonas, Kanes, Doherty); Department of Psychiatry, University of Michigan, Ann Arbor (Parikh); Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, New York (Iosifescu); Biogen, Cambridge, Mass. (Kotecha, Forrestal)., Jung J; Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville (Clayton); Sage Therapeutics, Cambridge, Mass. (Lasser, Jung, Jonas, Kanes, Doherty); Department of Psychiatry, University of Michigan, Ann Arbor (Parikh); Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, New York (Iosifescu); Biogen, Cambridge, Mass. (Kotecha, Forrestal)., Kotecha M; Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville (Clayton); Sage Therapeutics, Cambridge, Mass. (Lasser, Jung, Jonas, Kanes, Doherty); Department of Psychiatry, University of Michigan, Ann Arbor (Parikh); Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, New York (Iosifescu); Biogen, Cambridge, Mass. (Kotecha, Forrestal)., Forrestal F; Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville (Clayton); Sage Therapeutics, Cambridge, Mass. (Lasser, Jung, Jonas, Kanes, Doherty); Department of Psychiatry, University of Michigan, Ann Arbor (Parikh); Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, New York (Iosifescu); Biogen, Cambridge, Mass. (Kotecha, Forrestal)., Jonas J; Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville (Clayton); Sage Therapeutics, Cambridge, Mass. (Lasser, Jung, Jonas, Kanes, Doherty); Department of Psychiatry, University of Michigan, Ann Arbor (Parikh); Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, New York (Iosifescu); Biogen, Cambridge, Mass. (Kotecha, Forrestal)., Kanes SJ; Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville (Clayton); Sage Therapeutics, Cambridge, Mass. (Lasser, Jung, Jonas, Kanes, Doherty); Department of Psychiatry, University of Michigan, Ann Arbor (Parikh); Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, New York (Iosifescu); Biogen, Cambridge, Mass. (Kotecha, Forrestal)., Doherty J; Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville (Clayton); Sage Therapeutics, Cambridge, Mass. (Lasser, Jung, Jonas, Kanes, Doherty); Department of Psychiatry, University of Michigan, Ann Arbor (Parikh); Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, New York (Iosifescu); Biogen, Cambridge, Mass. (Kotecha, Forrestal).

Publikováno v: The American journal of psychiatry [Am J Psychiatry] 2023 Sep 01; Vol. 180 (9), pp. 676-684. Date of Electronic Publication: 2023 May 03.

Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.

Autor: Clayton AH; University of Virginia School of Medicine, Charlottesville, Virginia.; Corresponding author: Anita H. Clayton, MD, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, PO Box 800623, Charlottesville, VA 22908-0623 (ahc8v@hscmail.mcc.virginia.edu)., Lasser R; Sage Therapeutics, Inc, Cambridge, Massachusetts., Nandy I; Sage Therapeutics, Inc, Cambridge, Massachusetts., Sankoh AJ; Sage Therapeutics, Inc, Cambridge, Massachusetts., Jonas J; Sage Therapeutics, Inc, Cambridge, Massachusetts., Kanes SJ; Sage Therapeutics, Inc, Cambridge, Massachusetts.

Publikováno v: The Journal of clinical psychiatry [J Clin Psychiatry] 2023 Feb 20; Vol. 84 (2). Date of Electronic Publication: 2023 Feb 20.